1. Dill W.A., Peterson L., Chang T. Glazko A.J. (1965): Physiological disposition of α-methyl-α-ethylsuccinimide (ethosuximide, Zarontin®) in animals and in man. In: Abstracts of papers, 149th National Meeting, American Chemical Society, Detroit, Michigan, Abstr 30N.
2. Burkett A.R., Chang T. Glazko A.J. (1971): A hydroxylated metabolite of ethosuximide (Zarontin®) in rat urine. Fed. Proc., 30, 391.
3. Chang T., Burkett A.R. Glazko A.J. (1972): Ethosuximide — biotransformation. In: Woodbury D.M., Penry J.K., Schmidt R.P. Eds, Antiepileptic Drugs, 1st edn. New York, Raven Press, pp 425–429.
4. Horning M.G., Stratton C., Nowlin J., Harvey D.J. Hill R.M. (1973): Metabolism of 2-ethyl-2-methylsuccinimide (ethosuximide) in the rat and human. Drug Metab. Dispos., 1, 569–576.
5. Eadie M.J. Tyrer J.H. (1989): Anticonvulsant Therapy. Pharmacological basis and practice. 3rd edn. Churchill-Livingstone, Edinburgh.